CGTLive’s Weekly Rewind – January 12, 2024
Review top news and interview highlights from the week ending January 12, 2024.
CGTLive’s Weekly Rewind – January 12, 2024
Welcome to CGTLive™’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
1. FDA Activity Recap: December 2023 Features 2 Major Approvals, Meetings, and Clinical Holds
Catch up on any of the key FDA news stories you may have missed last month, with coverage highlights from the CGTLive™ team.
2. Mazyar Shadman, MD, on Investigating Treatment Choices With CAR-T and Auto-HSCT in LBCL
The associate professor at Fred Hutch Cancer Center discussed data from a retrospective analysis of patients treated with tisa-cel, axi-cel, or liso-cel.
3. Myasthenia Gravis mRNA CAR-T Demonstrates Clinically Meaningful Improvements in Phase 2a Trial
In terms of safety, Descartes-08 was characterized as well-tolerated during the study and long-term follow-up period.
4. Tami John, MD, on the FDA Approvals of Exa-cel and Lovo-cel
The clinical associate professor at Stanford Medicine also discussed ongoing trends in sickle cell disease research.
5. Vertex and CRISPR’s Ongoing Trial for Sickle Cell Disease Gene Therapy Seeks to Gather Patient Reported Outcomes
Exa-cel was recently approved for the treatment of SCD in the US, but data from the pivotal clinical trial continues to be collected.
Evaluating Allogeneic CAR-T P-BCMA-ALLO1 in R/R Multiple Myeloma
November 21st 2024Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center, discussed interim data from the phase 1/1b clinical trial evaluating Poseida's CAR-T.
World Pancreatic Cancer Day 2024: Looking Back at Progress in Cell and Gene Therapy
November 21st 2024In observance of World Pancreatic Cancer Day, held on the third Thursday of November each year, we took a look back at the past year's news in cell and gene therapy for pancreatic cancer indications.
